Share this page!

Enter URL or ID to Unroll

You can paste full URL like: https://x.com/threadreaderapp/status/1644127596119195649
or just the ID like: 1644127596119195649

How to get URL link on X (Twitter) App

  1. On the Twitter thread, click on or icon on the bottom
  2. Click again on or Share Via icon
  3. Click on Copy Link to Tweet
  4. Paste it above and click "Unroll Thread"!
  5. More info at Twitter Help
Toni Choueiri, MD Profile picture
@DrChoueiri
Dec 24, 2023 • 11 tweets • 9 min read • Read on X
Scrolly
It is this time of the year again: TOP 10 GU Oncology clinical papers/trials in 2023: Some negative, some positive, but we learned from all!

Feel free to add more & retweet & tag

This is not an exhaustive list!

@OncoAlert @danafarber @DanaFarber_GU

#OnwardFor2024 Image
1/#COSMIC-313 phase 3 trial shows ⬆️PFS with Cabozantinib plus Nivolumab and Ipilimumab in patients with previously untreated advanced or metastatic #RCC presented @myESMO #ESMO22

@motzermd @NEJM @tompowles1 @AlbigesL @DrDanielHeng @FabioSchutz78 @BurottoMauricio



COI: trial PInejm.org/doi/full/10.10…Image
2/In HRR-def #mCRPC: adding talazoparib to enza as 1L improved rPFS(HR=0.45), #PSA-progression, time to chemo, RR, could ⬆️OS (HR=0.69, immature) from Ph 3 #TALAPRO-2 trial. Presented #GU23 @ASCO

@neerajaiims @NatureMedicine #Fizazi @AzadOncology

nature.com/articles/s4159…


Image
Image
Image
3/ Addition of Nivolumab to Gem/Cis #chemotherapy as a 1L unresectable or #mUC significantly improves OS (HR=0.78) and PFS (HR=0.72). Presented #ESMO23 @myESMO

@MichvdHeijden @sonpavde @MattGalsky @NEJM @tompowles1

nejm.org/doi/full/10.10…

Image
Image
4/Encouraging data from phase3 #THOR trial: in patients with refractory post-PD1 #mUC with #FGFR3/2 alt resulted in ⬆️OS and PFS with ⬇️ TRAEs compared to chemotherapy.

@y_loriot @NEJM @GustaveRoussy #Siefker-Radtke

nejm.org/doi/full/10.10…


Image
Image
Image
5/More therapeutic option for #nccRCC! Results from phase 2 trial #KEYNOTEB61 support the use of Pembro+Lenvatinib as 1L therapy for patents with previously untreated advanced #nccRCC

@AlbigesL @ChungHanLee3 @TheLancetOncol @myESMO

thelancet.com/journals/lanon…

Image
Image
6/For patients with high-risk biochemical recurrent #PC: phase 3 #EMBARK shows that enzalutamide plus leuprolide and enzalutamide monotherapy were superior to leuprolide alone in term of metastasis-free survival!

@SFreedlandMD @nealshore @NEJM

nejm.org/doi/full/10.10…

Image
Image
7/ Encouraging prelim findings from #AMG-509(xaluritamig): T cell engager targeting #STEAP1 immunotherapy in patients with #mCRPC improves clinical outcomes. Phase I safe and tolerable.

#kelly @LenAppleman @CD_AACR

aacrjournals.org/cancerdiscover…


Image
Image
Image
8/This phase 2 trial demonstrated that #NAC in high-grade #UTUC was tolerated, and lead to ⬆️PFS and OS of responders compared to non responders. Kudos to the exceptional team @MSKCancerCenter GU Center @DrRosenbergMSK

@JCO_ASCO @bbmdmsk #Coleman #Bajorin

ascopubs.org/doi/pdf/10.120…Image
Image
Image
9/More on #RCC from#CONTACT-03 led by @montypal : 1st trial assessing #rechallenging with #ICI in #RCC with #anti-PDL1 didn’t show improvement of PFS and OS , w/ ⬆️toxicity.

@montypal @tompowles1 @TheLancet @ASCO @AlbigesL presented #ASCO23 @ASCO

thelancet.com/journals/lance…


Image
Image
Image
10/Promising data from this phase1 trial evaluating☢️ radioligand therapy with #ICI in patients with #mCRPC:a single priming dose of #LuPSMA followed by pembro maintenance was safe with confirmed OR.

@lawfong @thomashopemd @TheLancetOncol @myESMO

thelancet.com/journals/lanon…
Image

• • •

Missing some Tweet in this thread? You can try to force a refresh
　

Keep Current with Toni Choueiri, MD

Toni Choueiri, MD Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @DrChoueiri

Toni Choueiri, MD Profile picture
Jan 1
END OF YEAR TOP ALL CANCER TRIALS in 2024!

JUST in on 1 JAN 2025:

Paper 1:

#neoadjuvant checkpoint inhibitor Phase 3 trial in melanoma! #NADINA trial shows ipi+nivo significantly improves EFS vs. adjuvant nivo alone (HR 0.32, p<0.0001). #ASCO24 plenary #Melanoma @ASCO @ProfCUBlankNKI

nejm.org/doi/full/10.10…Image
Image
Paper 2:

The #TRANSMET study shows liver transplantation + chemo improves 5-year survival (56.6%) vs chemo alone (12.6%) for unresectable colorectal liver metastases. A potential game-changer in colorectal liver metastases! @TheLancetOncol



@GelliMaximilia1 @CHBPaulBrousse @GustaveRoussythelancet.com/journals/lance…Image
Paper 3:

The #TOPGEAR trial in @NEJM reveals: Adding preoperative chemoradiotherapy to perioperative chemo in resectable gastric cancer doubled pathological complete responses (17% vs 8%) but did not boost overall survival.

A step forward in understanding optimal strategies for gastric cancer treatment!

nejm.org/doi/full/10.10…
@Sydney_Uni @PeterMacRadOnc @OncoAlertImage
Image
Image
Read 11 tweets
Toni Choueiri, MD Profile picture
Dec 27, 2024
IT IS THIS TIME OF THE YEAR AGAIN!

TOP 10 GU Bladder/Kidney Cancer TRIALS FOR 2024

1/ Enfortumab Vedotin (EV) + Pembrolizumab new SOC for patients with metastatic #UC. Trial #EV302 displaced 30y Platinum-based combos
⏩ PFS benefit: 12.5 vs 6.3 mo (HR= 0.45)
⏩ OS benefit: 31.5 vs 16.1 mo (HR= 0.47)

@tompowles1 @NEJM #ESMO2023 Plenary

nejm.org/doi/full/10.10…Image
Image
2/NIAGARA trial: Perioperative durvalumab with NAC in operable bladder cancer à EFS and OS benefit.
⏩32% reduction in risk of recurrence/death
⏩ 25% reduction in the risk of death
⏩No new safety signals.
🎯Potential new SOC for cisplatin-eligible MIBC!

#ESMO2024 Plenary

@tompowles1 again @NEJM

nejm.org/doi/full/10.10…Image
Image
3/ Keynote-564: 1st phase 3 trial to demonstrate overall survival benefit for adjuvant treatment in #RCC #Pembrolizumab

⏩38% reduced risk of recurrence/death (HR 0.62)
⏩New SOC for high-risk RCC post-nephrectomy

@NEJM with @ASCO GU 2024 Image
Image
Read 10 tweets
Toni Choueiri, MD Profile picture
Dec 26, 2023
And now, onto the Top 10 Translational GU Papers of 20-23. Again, not an exhaustive list, with some our @DanaFarber @DanaFarber_GU being involved in.

Let us start! Image
1/#RCC histological subtypes display diverse epigenetic configurations. Allelic imbalances play a role in modifying TF binding sites, especially through candidate SNPs.

Potential targets for future investigations and therapeutic strategies?

@AminNassarMD @sarahaboualaiwi @SylvanBacaLab #FreedmanLab

nature.com/articles/s4146…Image
Image
Image
2/ Unlocking metastatic secrets: 🧬A novel #RCC model created with CRISPR-Cas9 editing reveals 9p21 disruption’s role, recurrent patterns driving progression, and #INF signaling’s

@perelli_luigi @LabGenovese @NatureCancer
nature.com/articles/s4301…

Image
Image
Read 11 tweets
Toni Choueiri, MD Profile picture
Dec 29, 2022
It is this time of the year again: TOP 10 GU Oncology clinical papers/trials in 2022:

Some negative, some positive, but we learned from all!

Feel free to add more & retweet & tag anyone involved

This is not an exhaustive list!

@OncoAlert @DanaFarber

#OnwardFor2023 Image
1/ #ARASENS phase 3 trial shows ⬆️OS with darolutamide in combination with docetaxel and ADT in #mHSPC (vs docetaxel + ADT alone) with similar AE profile, leading to @US_FDA approval.
#MatthewSmith @BertrandTOMBAL @MGHMedicine @NEJM
nejm.org/doi/full/10.10… ImageImageImage
2/ In #PCa patients with detectable PSA after prostatectomy, lymph node RT + ADT+ PBRT⬆️freedom from progression compared to ADT+ PBRT and PBRT alone according to #SPPORT trial.
@_APollack @DrHowardSandler @TheLancet
thelancet.com/journals/lance… ImageImage
Read 11 tweets
Toni Choueiri, MD Profile picture
May 27, 2022
Now that #ASCO22 abstracts are released, more insights into Top 10 #GUOnc abstracts (still many LBAs):

@DanaFarber_GU @OncoAlert @ASCO @ASCOPost

1/LBA| Chris Ryan @OHSUKnight=>The long awaited EVEREST study with adjuvant everolimus in RCC: stay tuned!
2/Interesting relationship between DepOR and clinical outcomes in CM-9ER! Greater proportions of pts receiving Nivo+Cabo had deeper responses vs SUN. This translated into better PFS/OS

Dr. Cristina Súarez @vallhebron Image
3/Better HEQOL baseline scores were associated with significantly reduced death on Checkmate-214. Pts with improved/stable 6mo-HRQoL had a 52% reduction in risk of death compared to pts who had worsened.
@CellaDavid @MSSatNU Image
Read 10 tweets
Toni Choueiri, MD Profile picture
Dec 28, 2021
It is this time of the year again: TOP 20 GU Oncology clinical trials published in 2021:

Some negative, some positive, some led to @FDAOncology approval; we learned from all!

Feel free to add & retweet & tag anyone involved

This is not an exhaustive list

@OncoAlert
1/ (177Lu)–PSMA-617 showing improved PFS and OS in pre-treated mCRPC patients vs. SOC, in addition to a favorable safety profile @sartor_oliver @morr316 @NEJM
nejm.org/doi/full/10.10…
2/ MRI with targeted & standard biopsy in men with MRI suggestive of prostate cancer (PC) was noninferior to standard biopsy for detecting clinically significant PC &resulted in less detection of clinically insignificant cancer @NEJM @TobiasNordstrom
nejm.org/doi/full/10.10…
Read 22 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

Send Email!

:(